Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill NVDA WeeklyPay ETF vs BIO-TECHNE Corp — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $36, while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Roundhill NVDA WeeklyPay ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| NVDW | TECH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $53.42 | $72.12 |
52-Week Low | $31.88 | $43.31 |
Market Cap | — | $11.16B |
Enterprise Value | — | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDW trades at $35.20, down 1.1% today, with technical indicators showing bearish momentum as moving averages signal strong selling pressure. The ETF maintains an active dividend distribution schedule with multiple payouts in recent months, though key valuation metrics remain unavailable for analysis. Current price action sits near support at $35 with resistance forming at $36.
The outlook remains cautious given the bearish technical signals and lack of fundamental data transparency. Investment opportunity exists primarily through the dividend income stream, though payout volatility presents risk. Market sentiment appears mixed with Seeking Alpha highlighting the ETF's role as a Nvidia hedge with variable yield characteristics.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
